Novanta Inc. account plan
Precision technology solutions provider
At a glance
Novanta supplies components and sub-systems to medical, life science and advanced industrial OEMs, with FY2025 revenue of $980.6 million.
Novanta Inc., founded in 1968 as General Scanning and organised as a holding company in Canada, engineers components and sub-systems that medical, life science and advanced industrial OEMs build into their own systems, sold mostly through a direct technical sales force. FY2025 revenue was $980.6 million (+3.3%), with operating income of $94.0 million and net income of $53.8 million; the medical market was approximately 53% of revenue and the United States 52.9%. It had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia. Customer concentration is high: the top ten customers made up approximately 42% of 2025 sales. The July 2026 acquisition of Riverpoint Medical, the largest in its history, raises its medical share further.
Business units
Robotics and Automation (Automation Enabling Technologies)
about 32% of FY2025 revenue ($318.6 million)Precision motion, servo drives, force torque and position sensors, robotic end-of-arm tooling and air bearing spindles for industrial, medical, warehouse and humanoid robots and semiconductor work. Revenue rose $30.3 million in 2025 and 17.3% in Q3 2026; air bearing spindles are sold out for two years.
Precision Manufacturing (Automation Enabling Technologies)
about 19% of FY2025 revenue ($182.3 million)Laser beam steering and scanning solutions and laser sources for additive manufacturing, laser marking, micromachining, metrology and PCB and semiconductor manufacturing. Revenue declined $20.0 million in 2025 but grew 13.7% in Q3 2026. AET is led by Co-COO Chuck Ravetto.
Advanced Surgery (Medical Solutions)
about 25% of FY2025 revenue ($242.4 million)Insufflators, endoscopic pumps, fluid management and related consumables for minimally invasive surgery, now including Riverpoint Medical's sutures and implantable materials. Revenue rose $33.7 million in 2025 and the unit grew 12% organically in Q3 2026. Medical Solutions is led by Co-COO John Lesica.
Precision Medicine (Medical Solutions)
about 24% of FY2025 revenue ($237.3 million)Imaging, identification and RFID solutions (including Keonn), motion control subsystems for life science and medical equipment, optical light engines and operating room video technologies. Revenue fell $12.6 million in 2025 and 5% in Q3 2026 after a decision not to pursue lower-margin business.
Strategic priorities
- More medical, more recurring
- Management steers toward medical end markets, now 53% of revenue and approaching 60% on a full-year basis with Riverpoint, and recurring consumables, roughly 25% of revenue.
- Organic growth through new products
- Long-term algorithm of mid to high single-digit organic growth; new product revenue rose 23% in Q3 2026 and advanced surgery targets approximately $400 million in revenue by 2030.
- Deleveraging after Riverpoint
- The near-term capital deployment priority is to delever; net leverage stood at 2.2 at the end of Q3 2026.
- Regional manufacturing footprint
- Regionalize manufacturing into centers of excellence and go from 21 to 18 factories by end of Q1 2027, under a restructuring program costing about $25.0 million in total by end-2026.
- Physical AI and robotics
- Grow in robotics, which management describes as a roughly $2 billion addressable market growing about 10% a year, including warehouse automation and humanoids.
Latest results
In Q3 2026 (quarter ended 2 October 2026) revenue rose 23.1% to $305.0 million, with Riverpoint Medical adding $32.9 million and organic growth of nearly 10%. Automation Enabling Technologies grew 16.0% to $145.4 million with a 50.2% gross margin, while Medical Solutions grew 30.3% to $159.7 million but its gross margin fell to 39.9%. Operating income fell 36.3% to $13.9 million on acquisition, restructuring and amortization costs, while adjusted EBITDA rose 38% to $80 million. Backlog was $543 million. Full-year 2026 guidance is revenue of $1,135-1,140 million, adjusted EBITDA of $274-277 million and operating cash flow of about $200 million, with a production slowdown at the Stockport (U.K.) factory weighing on Q4 margins.
Investments and deals
- Riverpoint Medical
- Minimally invasive surgical consumables maker acquired on 23 July 2026 for $1,200.6 million upfront net of cash, plus a $250.0 million milestone payable by 8 January 2027.
- Keonn Technologies
- Barcelona RFID specialist acquired on 8 April 2025 for EUR 64.8 million ($71.0 million) net of cash, with up to EUR 20.0 million contingent consideration.
- Acquisition funding
- $613.1 million net from 6.50% tangible equity units in November 2025, a $300 million private placement at $140.00 per share in June 2026, and a $200.0 million delayed draw term loan.
- New financial and operations system
- A new ERP system is being implemented, with SAP MRP live at two lighthouse sites; it was a cost driver in 2025.
- China spindle capacity
- A customer-co-funded China expansion for air bearing spindles should be fully ramped by April 2027.
Challenges and risks
- Customer concentration
- Two medical OEMs represented approximately 12% and 11% of 2025 revenue and the top ten customers approximately 42%.
- Factory transfers and margins
- Regional manufacturing transfers created dual running costs; the Stockport production slowdown is roughly a 200 basis point gross margin headwind in Q4 2026.
- Component and rare-earth supply
- Shortages of components from AI-related demand, Chinese export licences on rare-earth materials and magnets, tariffs, and higher energy and freight costs from the 2026 Iran conflict.
- Higher leverage
- Riverpoint was funded with $616.0 million of revolver and delayed draw borrowings, taking leverage to 2.43 against a 4.00 covenant.
- Precision medicine softness
- Precision medicine sales fell 5% in Q3 2026 and life science volume is lower; a return to growth is expected in late 2027.
What leadership says
“more medical, more recurring, and less cyclical”
“Our near-term capital deployment priority is to delever”
“A design win in one business becomes the invitation into the next.”
“Operating in region for region with a supply base close to our factories and our customers is proving to be a real advantage.”
Where a supplier can help
- Regional supply base
- The regional manufacturing footprint and tight rare-earth and electronic component supply create demand for in-region suppliers of magnets, electronic components and materials close to Novanta factories.
- Factory consolidation support
- Closing factories down to 18 and the Stockport slowdown point to needs in manufacturing transfer, quality testing and production engineering services.
- ERP and operations systems
- The ongoing financial and operations system implementation, with SAP MRP at lighthouse sites, opens room for ERP integrators and supply-chain planning tools.
- Riverpoint integration
- Integrating the largest acquisition in its history while deleveraging favours integration, procurement savings and medical consumables manufacturing partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Novanta Inc.?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Novanta Inc. Form 10-K for fiscal year 2025 (year ended December 31, 2025)
- Novanta Inc. is a global supplier of core technology solutions (components and sub-systems) to medical, life science and advanced industrial OEMs; founded in 1968 as General Scanning, renamed Novanta in May 2016 and organised as a holding company in Canada.
- FY2025 revenue was $980.6 million (+3.3%), of which the 2025 acquisition (Keonn) added $21.8 million and FX $14.6 million; operating income fell 15.0% to $94.0 million and diluted EPS to $1.47 from $1.77.
- Two reportable segments: Automation Enabling Technologies ($500.8 million, 47.8% gross margin, $114.5 million operating profit) and Medical Solutions ($479.8 million, 41.6% gross margin, $51.2 million operating profit).
- The medical market was approximately 53% of revenue and advanced industrial approximately 47%; the United States was 52.9% of revenue, and approximately 47% came from customers outside the U.S.
- Customer concentration is high: two medical OEMs represented approximately 12% and 11% of revenue, and the top ten customers approximately 42%.
- Strategy: raise the medical share of revenue (new products in minimally invasive and robotic surgery, ophthalmology, drug delivery, clinical lab), key account management and cross-selling to medical OEMs, medical technology acquisitions, and regionalize the manufacturing footprint into centers of excellence.
- The 2025 restructuring program (regionalized manufacturing, site closures) cost $14.0 million in 2025, with about $25.0 million expected in total by end-2026; operating cash flow fell to $64.1 million from $158.5 million on higher inventory.
- Balance sheet reloaded for M&A: $613.1 million net proceeds from 6.50% tangible equity units issued in November 2025, an $850.0 million revolver undrawn at year end, cash of $380.9 million; a $200.0 million buyback plan was approved in September 2025.
- About 3,000 employees (36% U.S., 55% Europe, 9% Asia), of which approximately 600 in engineering; backlog $481.2 million at 31 December 2025.
- Novanta Inc. Form 10-Q for the third quarter of 2026 (quarter ended October 2, 2026)
- Q3 2026 (quarter ended 2 October 2026) revenue was $305.0 million, +23.1%, of which the Riverpoint Medical acquisition added $32.9 million (13.3%); nine-month revenue $828.5 million, +14.7%.
- Automation Enabling Technologies revenue rose 16.0% to $145.4 million, with robotics and automation products +17.3% and precision manufacturing +13.7%; its gross margin reached 50.2% (47.3% a year earlier) and operating margin 28.1%.
- Medical Solutions revenue rose 30.3% to $159.7 million, but its gross margin fell to 39.9% (43.0%) and operating margin to 6.0% because of acquisition amortization and site-closure costs.
- Riverpoint Medical (minimally invasive surgical consumables) closed on 23 July 2026 for $1,200.6 million upfront, net of cash, plus a $250.0 million milestone payable by 8 January 2027.
- Funding: a $300 million private placement at $140.00 per share (June 2026), a $200.0 million delayed draw term loan and revolver borrowings; leverage ratio 2.43 against a 4.00 covenant.
- Q3 operating income fell 36.3% to $13.9 million and diluted EPS to $0.05, on $23.1 million of restructuring and acquisition costs and $14.7 million of intangible amortization.
- Nine-month operating cash flow jumped to $155.9 million from $55.3 million, helped by a customer supply-agreement payment and bonuses converted to equity.
- Supply risks named: AI-driven component shortages, Chinese export licences on rare-earth materials and magnets, tariffs, and the 2026 Iran conflict raising energy and freight costs.
- Novanta Q3 2026 earnings call transcript
- CEO Matthijs Glastra called Q3 2026 "a milestone quarter": revenue +23% to $305 million, organic growth of nearly 10% (best in more than three years), adjusted EBITDA +38% to $80 million at a record 26% margin, adjusted EPS +21% to $1.05.
- Bookings grew 29% (18% excluding Riverpoint Medical), book-to-bill 1.08, backlog $543 million; new product revenue +23% and vitality index about 27% of sales year to date.
- Direction: "more medical, more recurring, and less cyclical"; medical is 53% of revenue, approaching 60% for a full year with Riverpoint; recurring consumables are roughly 25% of revenue; embedded-software intelligent subsystems roughly 25% of revenue and about 75% of launches.
- Riverpoint Medical contributed about $33 million in the quarter, in line with plan; Medical Solutions now reports two business units, advanced surgical technologies (+12% organic) and precision medicine (-5%).
- AET grew 16% on semiconductor, robotics and advanced manufacturing (together roughly 40% of pro forma revenue); air bearing spindles are sold out for two years and the business should double by 2028.
- A production slowdown at the Stockport (U.K.) factory is a roughly 200 basis point gross margin headwind in Q4; restart expected in Q1 2027.
- 2026 guidance: revenue $1,135-1,140 million (about 7% organic), adjusted EBITDA $274-277 million, adjusted EPS $3.66-3.71, operating cash flow about $200 million; 2027 seen at more than 15% reported growth and more than 20% adjusted EBITDA growth.
- Priorities: organic growth, deleveraging after Riverpoint, and 18 factories by end of Q1 2027 (from 21); Julie Eaton, ex-Halma, hired as President of robotics and automation.
- Novanta Q4 and full-year 2025 earnings call transcript
- On the Q4 2025 call (24 February 2026), CEO Matthijs Glastra reported record quarterly revenue (+9% reported, +2% organic) and bookings up 25% with a 1.11 book-to-bill; every business had double-digit bookings growth for the first time since 2022.
- Full-year 2025 revenue reached $981 million; full-year bookings grew 14%; new product sales grew over 60% and the vitality index was 22%.
- Q4 margins and cash flow missed the November guidance because Novanta "prioritized customer deliveries over the pace of our regional manufacturing transfers"; costs were adjusted in January.
- Growth platforms (next-generation insufflation, robotic surgery, physical AI for warehouse automation and humanoids, intelligent laser beam steering) are "a $4 billion incremental market opportunity by 2030"; advanced surgery targets approximately $400 million in revenue by 2030.
- Air bearing spindles are "the only qualified supplier for drilling AI-driven GPU boards", growing at a strong double-digit rate.
- M&A: "the largest acquisition pipeline in my tenure as CEO", focused on medical technologies, medical consumables, bioprocessing and embedded software, with nearly $1.5 billion of capacity after raising more than $600 million.
- 2026 guidance: revenue about $1,030-1,050 million (4% to 6% organic), adjusted gross margin about 47%, adjusted EBITDA $245-250 million, adjusted EPS $3.50-3.65, operating cash flow $145-185 million.
- Medical consumables were 15% of 2025 sales and growing double digits; medical exposure has grown to close to 55% of revenue "up from 10%" under Glastra.
Questions about Novanta Inc.
What does Novanta do?
Novanta engineers components and sub-systems, such as laser beam steering, precision motion, robotic tooling, surgical insufflators, pumps and consumables, that medical, life science and advanced industrial OEMs integrate into their own systems.
What is Novanta's revenue?
FY2025 revenue was $980.6 million, up 3.3%. Novanta guides to 2026 revenue of $1,135-1,140 million, including Riverpoint Medical.
How many employees does Novanta have?
Novanta had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia.
Who leads Novanta?
Matthijs Glastra is Chair of the Board and CEO, Robert Buckley is CFO, and John Lesica and Chuck Ravetto are Co-Chief Operating Officers.
What is Novanta's strategy?
Become more medical, more recurring and less cyclical through new products, medical acquisitions such as Riverpoint Medical, and a regionalized manufacturing footprint, while delevering in the near term.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)